• Share:

Funding

Targeted Therapies in Melanoma

Principal Investigator: Meenhard Herlyn

Agency: National Cancer Institute

Type: PO1 (CA114046-03)

Years 5-10, Period: May 16, 2008 to Oct. 1, 2018

Subproject 1: Senescence as an endpoint in melanoma therapy

 

Human Melanoma: Etiology, Progression, and Therapy

Principal Investigator: Meenhard Herlyn

Agency: NIH/NCI

Type: P01-Program Project (CA25874),

Years 30-34, Period: May 1, 2011 to April 30, 2016

Subproject on grant: Cellular mechanisms of therapy resistance

 

Biology of Melanoma Metastasis

Principal Investigator: Meenhard Herlyn

Agency: National Cancer Institute

Type: R01 (CA47159)

Years 21-25, 2011-2016

 

Cell-Cell Communication During Melanoma Progression

Principal Investigator: Meenhard Herlyn

Agency: National Cancer Institute

Type: R01 (CA76674)

Years 15-19, Period: April 1, 2011 to March 31, 2016

 

The Role of Genetic Susceptibility in Melanoma Development

Principal Investigator: Meenhard Herlyn

Agency: National Cancer Institute

Type: R01 (CA182890)

Years 1-5, Period: May 1, 2014 to April. 30, 2019

 

SPORE in Skin Cancer

Principal Investigator: Meenhard Herlyn

Agency: National Cancer Institute

Type: SPORE (CA174523)

Years 1-5, Period: September 16, 2014 to September 15, 2019

 

OTHER FUNDING

 

From the Human Genome to Genes in Melanocytes and Melanoma Cells

Agency: NOFMR – Noreen O’Neill Foundation for Melanoma Research

Period: September 15, 2014 to September 15, 2015

 

Drivers in Melanoma Susceptibility, Development and Progression

Agency: Melanoma Research Alliance (Team Science Award)

  Period: May 1, 2013 to April 30, 2016